Drugs / DNL747
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03757325 | Feb → Dec 2019 | Alzheimer disease | Denali Therapeutics Inc. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2020-06-09 | Denali Therapeutics Inc. | Results Denali Therapeutics Provides Broad Update on Its RIPK1 Program Partnered With Sanofi denalitherapeutics.com ↗
Safety endpoints were met in Phase 1b patient studies with DNL747 in ALS and Alzheimer’s disease, however further dose escalation to achieve higher levels of target inhibition may be limited by preclinical chronic safety data |
| 2018-11-19 | Denali Therapeutics Inc. | Results Denali Therapeutics Announces Positive Clinical Results With Its Lead RIPK1 Inhibitor Molecule and Intention to Initiate Patient Studies in Multiple Indications in Collaboration With Sanofi denalitherapeutics.com ↗
DNL747 achieved its safety, pharmacokinetic, and pharmacodynamic objectives. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-06-09 | Denali Therapeutics Inc. | Denali Therapeutics Provides Broad Update on Its RIPK1 Program Partnered With Sanofi denalitherapeutics.com ↗ |
| 2019-02-15 | Denali Therapeutics Inc. | Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for Alzheimer’s Disease denalitherapeutics.com ↗ |
| 2019-01-08 | Denali Therapeutics Inc. | Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for ALS denalitherapeutics.com ↗ |
| 2018-11-19 | Denali Therapeutics Inc. | Denali Therapeutics Announces Positive Clinical Results With Its Lead RIPK1 Inhibitor Molecule and Intention to Initiate Patient Studies in Multiple Indications in Collaboration With Sanofi denalitherapeutics.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DNL747 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03757325 ↗ |
| Known as | SAR443060 | “SAR443060 (previously DNL747) is a selective, orally bioavailable, central nervous system (CNS)-penetrant, small-molecule, reversible inhibitor of RIPK1.” PMID 35649245 ↗ Jun 2022 |
| Action | Inhibit | “reversible inhibitor of RIPK1” PMID 35649245 ↗ Jun 2022 |
| Modality | Small molecule | “SAR443060 (previously DNL747) is a selective, orally bioavailable, central nervous system (CNS)-penetrant, small-molecule, reversible inhibitor of RIPK1.” PMID 35649245 ↗ Jun 2022 |
| Route | Oral | “multiple oral doses of DNL747” NCT03757325 ↗ |
| Target | RIPK1 | “reversible inhibitor of RIPK1” PMID 35649245 ↗ Jun 2022 |